The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.92% | -3.7% | 9.65% | 10.62% | N/A | N/A | N/A | N/A | N/A | N/A | 4.51% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.92% | -3.7% | 9.65% | 10.62% | N/A | N/A | N/A | N/A | N/A | N/A | 4.51% |
| Rank within category | 13/19 | 11/18 | 12/18 | 13/18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sector Funds | 2025 | 2026 |
|---|---|---|
| Yearly returns | N/A | 6.8% |
| Q1 returns | N/A | -5.93% |
| Q2 returns | N/A | 16.32% |
| Q3 returns | N/A | 2.44% |
| Q4 returns | N/A | -4.72% |
0.50% on or before 30D, Nil after 30D
| Alpha | 1.70722 |
| Beta | 0.6089 |
| Sharpe Ratio | 0.15262 |
| Sortino Ratio | 0.306733 |
| R-Squared | 0.2894 |
| Tracking Error | 3.9836 |
| Downside Risk | 10.9681 |
| Std. Deviation (Annualised) | 15.1627 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Bandhan Healthcare Fund - Regular Plan - Growth Current | -7.92% | -3.7% | 9.65% | 10.62% | N/A | N/A | N/A | N/A | 4.51% | 326.54 | 2.83 | 0.15 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.74% |
| Triparty Repo TRP_011026 | Cash & Cash Equivalents and Net Assets | 6.72% | |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.18% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 5.75% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 5.27% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.35% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.27% |
| Shilpa Medicare Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.17% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.10% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.78% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.39% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.23% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.11% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.82% |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 2.74% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 2.46% |
| Rainbow Children's Medicare Ltd. | Healthcare Services | Domestic Equities | 2.21% |
| Eris Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.19% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.14% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 1.88% |
| Evonile Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.88% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.54% |
| Sanofi India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.50% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.48% |
| Healthcare Global Enterprises Ltd. | Healthcare Services | Domestic Equities | 1.33% |
| Thyrocare Technologies Ltd. | Healthcare Services | Domestic Equities | 1.31% |
| Jubilant Pharmova Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.26% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.22% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.17% |
| Sai Parenteral's Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.15% |
| Alivus Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.15% |
| Astrazeneca Pharma India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.14% |
| Orchid Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.13% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 0.91% |
| Medi Assist Healthcare Services Ltd. | Insurance | Domestic Equities | 0.83% |
| Viyash Scientific Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.77% |
| Cash Margin - CCIL | Cash & Cash Equivalents and Net Assets | 0.04% | |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | -0.31% | |
| Total | 100.00% | ||
Mr. Shah is associated with Bandhan AMC since August 2015 as part of the Fixed Income Team and will now be handling investments and fixed income fund management.Prior experience:1) IDBI Asset Management Ltd. - Dealing in Fixed income (Jan. 2013 to Aug. 2015)2) India Bulls Asset Management Ltd. - Dealing in Fixed income (Jun. 2011 to Dec. 2012)3) Mata Securities - Relationship Manager, Wholesale Debt Market (Jun. 2010 to Jun. 2011)4) Twenty First Century - Relationship Manager, Wholesale Debt Market (Jan. 2009 to May 2010)
Viraj Kulkarni serves as a Senior Analyst and Fund Manager in the Equity Fund management team at Bandhan AMC. With a focus on sectors such as IT Services, Cement, and Building materials, he brings nearly a decade of sector-specific expertise and insights. Prior to joining Bandhan AMC, Viraj was associated with Franklin Templeton from May 2014 to September 2015 and had a tenure at Goldman Sachs from 2010 to 2012. His educational credentials include a Post Graduate Diploma in Management (PGDM), a Chartered Financial Analyst (CFA) certification, and a B. Tech degree in Electrical & Electronics.
Ms. Ritika Behera has joined Bandhan AMC Limited as Vice President - Equities on August 10, 2023 in Equity Investments team. In her role she will be responsible for research and analysis. She has total experience of more than 13 years.
Mr. Gaurav Satra joined the Equity Fund Management team of Bandhan AMC in June 2022 and was designated as the Equity Dealer. He has total experience of more than 7.5 years. Priorto the same, he was associated with variousConsultancy Firms as a CA from December 2016 to May 2022.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
